Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

mber 31, 2012 was $46.2 million, or $0.66 and $0.62 income per basic and diluted earnings per share, respectively, compared to non-GAAP net income of $58.6 million, or $0.85 and $0.82 income per basic and diluted earnings per share, respectively for the quarter ended December 31, 2011.

Revenue for the six months ended December 31, 2012 was $160.7 million compared to $77.9 million for the six months ended December 31, 2011. Revenue for the quarter ended December 31, 2012 was $58.0 million compared to $77.9 million for the quarter ended December 31, 2011. Revenue for the quarter ended December 31, 2012 consisted primarily of $50.0 million of milestone revenue due to the Company's achievement of one clinical milestone in connection with the Company's collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. and its affiliates ("Janssen") and $5.0 million of license revenue related to the Company's license agreement with Novo Nordisk A/S under which Novo Nordisk A/S acquired the exclusive worldwide rights for the Company's small molecule Factor VIIa inhibitor, PCI-27483, in a restricted disease indication outside of oncology.

To date, the Company has received three milestone payments from Janssen of $50 million each, totaling $150 million, under the Agreement. The Company may receive up to an additional $675 million in development and regulatory milestone payments, however, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general Janssen is responsible for approximately 60% of development costs and the Company is responsible for 40% of development costs. The Agreement with Janssen also provides for a $50 million annual cap of the Company's share of development costs and pre-tax commercialization losses for each calendar year. Under the Agreeme
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... , ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately ... for the three years through 2014. Being named to the Inc. 5000 list designates ... country. , “We are thrilled to make the Inc. 5000 list for 2015,” ...
(Date:8/26/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended June 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... to our Oral Amp B program, rapidly advancing ... Andrew Rae , President & CEO of ...
(Date:8/26/2015)... 26, 2015 Intrexon Corporation (NYSE: XON ... closing of its previously announced public offering of common ... of their option to purchase an additional 731,707 shares ... $41.00 per share.  The exercise of the underwriters, option ... sold by Intrexon to 5,609,756 shares and increased the ...
(Date:8/26/2015)... ... , ... PRC Clinical, a Clinical Trial Management Expert CRO, will ... southern California. The Clinical Trial Management Expert CRO seeks to introduce more California-based sponsors ... , Stem Cell Meeting on the Mesa on October 7-9 ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... (OTC Bulletin Board: GNTA) announced today that the ... accredited,investors to place Senior Secured Convertible Notes due ... gross proceeds before fees and expenses. The,closing of ... to take place on or,about June 6, 2008, ...
... Mich., June 5 Compendia Bioscience today,announced ... agreement with,GlaxoSmithKline (NYSE: GSK ) for ... flagship product, Oncomine.,Oncomine Enterprise Edition builds upon ... by integrating the ability to securely,view proprietary ...
... SAN FRANCISCO, Calif., June 5 Exelixis,Inc. (Nasdaq: ... into an,agreement with Deerfield Management, a leading healthcare investment,organization ... $150.0 million in financing through a flexible credit facility. ... next 18 months at Exelixis,discretion. Exelixis is under no ...
Cached Biology Technology:Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 2Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 3Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 4GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience 2Exelixis Receives $150 Million Funding Commitment From Deerfield Management 2Exelixis Receives $150 Million Funding Commitment From Deerfield Management 3Exelixis Receives $150 Million Funding Commitment From Deerfield Management 4Exelixis Receives $150 Million Funding Commitment From Deerfield Management 5
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, ... on improving the user experience and security of ... technologies, today announced that its TrulySecure™ ... authentication software to be FIDO Certified™. ... for compliance with the FIDO UAF (Universal Authentication ...
(Date:8/18/2015)... , Aug. 17, 2015 Research ... addition of the "Global Biometric Authentication & ... - Estimation & Forecast, 2015-2020" report to ... authentication and identification systems market is expected to ... 2015 to 2020 and generate over $25 billion ...
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... Voelker, PhD, professor of medicine at National Jewish ... for various lipids and related compounds that can ... those caused by influenza and respiratory syncytial virus ... has published several scientific papers describing a naturally ...
... is available in Spanish . Professor ... University of the Basque Country and Director of the Biophysics ... award. This award is the most important in the world ... Biophysics has issued this award, but this year for the ...
... that certain Australian native flowers have shifted away from using ... red hues favoured by birds. In a study published ... RMIT University have shown for the first time that Australian ... signatures that are best discriminated by those birds. Dr ...
Cached Biology News:Felix Goñi, Avanti award for best European research in lipids 2For birds, red means 'go' 2
... , 25 g Blocking Reagent , 2 x ... T7 Elution Buffer , 0.2 ml BL21 glycerol stock ... ml BLT5615 glycerol stock , 1010 pfu T7Select Positive ... , 50 l S-protein HRP Conjugate , 2 ...
... WesternBreeze Immunodetection Kits are designed ... immobilized on nitrocellulose or PVDF membranes. ... (except membranes and primary antibodies), the ... both optimizing your protocol and getting ...
... Mouse Monoclonal to L1 Cell Adhesion Molecule ... is located in Xq28, is involved in ... the aqueduct of Sylvius); 2) MASA (mental ... 3) SPG1 (spastic paraplegia). Immunogen: ...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: